FSN Capital to acquire a majority stake in Epista Life Science
The leading Nordic private equity firm, FSN Capital, has signed an agreement to acquire a majority stake in Epista Life Science A/S and enters into a continuous partnership with the founder Klavs Esbjerg, CEO, who will retain a sizeable stake in the company. Plesner acted as legal counsel for FSN Capital.
FSN Capital has agreed to acquire a majority stake in Epista Life Science. Epista Life Science, headquartered in Hørsholm and with offices in Germany and Sweden, is an experienced and highly specialised IT service provider offering high-end services, including general consulting, software implementation and managed operations, to leading international pharmaceutical, biotech and medical device companies.
Epista Life Science assists customers to define and execute digital IT strategies by facilitating the adoption of technology while ensuring continuous regulatory compliance (FDA, EMA and more) throughout the entire value chain. With a competent management team, a well-defined business strategy and a value-driven approach, Epista Life Science has managed to grow considerably by more than 30% per annum since inception, with DKK 119m in revenue in 2021 and over 100 employees.
Epista Life Science was founded in 2009 by Klavs Esbjerg, who will re-invest and continue as CEO of the company. By the recent acquisition of Swedish Bruun and Maté and with strong M&A and organic growth pipeline, Epista Life Science is expected to continue its fast-growing journey and create a global force in the intersection between business priorities, IT services and compliance requirements in the life science industry.
Plesner's core M&A team on the transaction was Henrik Rossing Lønberg, Kristian Vinter Bisgaard and Annemette Guldborg Jensen.